ArticleFrontiers in medicine2025
Incidence of eye problems in children aged 3-6 years during and after the COVID-19 pandemic.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Incidence of eye problems increased during the COVID-19 pandemic when home confinement measures were adopted. The aim of this study was to investigate the changes of incidence of eye problems after the ending of COVID-19 pandemic. Methods: Vision screening results were retrospectively extracted from the health examination results of children from Southwestern China who were aged 3-6 years in either 2022 or 2023. After interpretation of the vision screening results using an official standard, percentages of abnormal vision screening results were calculated and compared between year 2022 and 2023 using statistical software. Results: In all, vision screening results were extracted from 26396 children in 2022 and 31324 children in 2023. The standardized overall incidence of eye problems was 9.13% in 2022, and 8.78% in 2023. The standardized incidence of myopia, hyperopia, astigmatism, and anisometropia were 0.84%, 0.55%, 8.64%, and 0.87% in 2022, and 0.60%, 0.61%, 8.06%, 0.45% in 2023, respectively. Logistic regression showed that odds of having eye problems, myopia, astigmatism, or anisometropia were significantly lower in 2023. Conclusion: In the cohort of children aged 3-6 years, the overall incidence of eye problems and incidence of myopia, astigmatism and anisometropia was lower in 2023, together with higher incidence of hyperopia in 2023. Incidence of astigmatism was much higher than that of other types of eye problems. More efforts should be made to lower the incidence of astigmatism in pre-school children, as well as understand the underlying mechanism on the impact of COVID-19 on the eye health of pre-school children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.